Medical News

RSS

3SBio, DaVita partner to offer dialysis services in NE China

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) today announced it has entered into an agreement with 3SBio Inc., a leading Chinese biotechnology developer of biopharmaceutical products, to establish a joint venture for providing dialysis treatments in northeastern China.

9 Mar 2012

PhotoMedex fourth quarter revenues increase 26% to $28.8M

PhotoMedex, Inc. today reported financial results for the three and 12 months ended December 31, 2011.

9 Mar 2012

Avedro submits VibeX/KXL System NDA with FDA to treat keratoconus, corneal ectasia

Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.

9 Mar 2012

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the Michael E. DeBakey Veterans Affairs Medical Center, in Houston, Texas, has initiated a Phase 2A trial assessing the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130 (macimorelin), in patients with cancer cachexia.

9 Mar 2012

ICON's Nuloy Coronary Stent System receives CE Mark

Medical device company ICON Interventional Systems, Inc. today announced it has received the CE Mark for the Nuloy Coronary Stent System, a next generation coronary stent made from a proprietary Molybdenum and Rhenium (MoRe) alloy.

9 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

Infection with M. genitalium may double African women's HIV risk

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, reports a study in the March issue of AIDS.

9 Mar 2012

Not all patients with CKD are destined for kidney failure

Not all patients with chronic kidney disease (CKD) are destined for kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

9 Mar 2012

Celgene acquires Avila Therapeutics

Celgene Corporation today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila's discovery program.

9 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

NCCN issues new guidelines for AYA oncology patients

The National Comprehensive Cancer Network announces that it has issued new NCCN Clinical Practice Guidelines in Oncology for Adolescent and Young Adult (AYA) Oncology. AYA patients are defined in the guidelines as individuals 15 to 39 years of age at initial cancer diagnosis.

9 Mar 2012

Omega Protein fourth quarter revenues increase 46% to $62.8M

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the fourth quarter and full year ended December 31, 2011.

8 Mar 2012

New ultrasound technique for rapid and accurate assessment of osteoporosis

Laser-based measurements are proving to be a promising method for the assessment of osteoporosis. The team led by Professor Jussi Timonen has developed an ultrasound technique that use laser beams for a rapid and accurate assessment of osteoporosis.

8 Mar 2012

Researchers identify specific gene linked with throat cancer

Researchers at King's College London and Hiroshima University, Japan, have identified a specific gene linked to throat cancer following a genetic study of a family with 10 members who have developed the condition.

8 Mar 2012

FDA clears Abbott's FreeStyle InsuLinx Blood Glucose Monitoring System

Abbott today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System, the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients.

8 Mar 2012

Cantel second quarter net income increases 28% to $7,294,000

CANTEL MEDICAL CORP. reported a 28% increase in net income to a record $7,294,000, or $0.27 per diluted share, on a 20% increase in sales to a record $97,297,000 for the second quarter ended January 31, 2012.

8 Mar 2012

Exposure to MSS could help reduce cardiorespiratory events in preterm infants

When babies are born prematurely, they are thrust into a hospital environment that while highly successful at saving their lives, is not exactly the same as the mother's womb where ideal development occurs. The Neonatal Intensive Care Unit (NICU) is equipped with highly skilled care givers and incubators that regulate temperature and humidity, but Amir Lahav, ScD, PhD, director of the Neonatal Research Lab at Brigham and Women's Hospital (BWH) thought that something was missing - simulation of the maternal sounds that a baby would hear in the womb.

8 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

FDA approves Teva's ProAir HFA with dose counter for asthma, COPD and EIB

Teva Respiratory announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir HFA with a dose counter for use in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

8 Mar 2012